Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 248.12 Billion KRW | -4.52% |
| 2022 | 259.87 Billion KRW | 45.71% |
| 2021 | 178.35 Billion KRW | 96.78% |
| 2020 | 90.63 Billion KRW | 9.21% |
| 2019 | 82.99 Billion KRW | 17.02% |
| 2018 | 70.92 Billion KRW | 49.03% |
| 2017 | 47.59 Billion KRW | 21.5% |
| 2016 | 39.17 Billion KRW | -21.02% |
| 2015 | 49.59 Billion KRW | 1130.78% |
| 2014 | 4.02 Billion KRW | 51.02% |
| 2013 | 2.66 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 276.28 Billion KRW | 1.65% |
| 2024 Q1 | 271.8 Billion KRW | 9.54% |
| 2023 Q4 | 248.12 Billion KRW | -13.67% |
| 2023 FY | 248.12 Billion KRW | -4.52% |
| 2023 Q1 | 286.33 Billion KRW | 10.18% |
| 2023 Q2 | 280.65 Billion KRW | -1.98% |
| 2023 Q3 | 287.42 Billion KRW | 2.41% |
| 2022 Q2 | 208.37 Billion KRW | -2.02% |
| 2022 Q3 | 261.89 Billion KRW | 25.68% |
| 2022 FY | 259.87 Billion KRW | 45.71% |
| 2022 Q1 | 212.66 Billion KRW | 19.24% |
| 2022 Q4 | 259.87 Billion KRW | -0.77% |
| 2021 Q2 | 167.56 Billion KRW | 76.76% |
| 2021 Q4 | 178.35 Billion KRW | 9.49% |
| 2021 Q3 | 162.89 Billion KRW | -2.79% |
| 2021 FY | 178.35 Billion KRW | 96.78% |
| 2021 Q1 | 94.79 Billion KRW | 4.59% |
| 2020 Q2 | 89.29 Billion KRW | 6.53% |
| 2020 Q3 | 83.92 Billion KRW | -6.02% |
| 2020 FY | 90.63 Billion KRW | 9.21% |
| 2020 Q1 | 83.82 Billion KRW | 1.0% |
| 2020 Q4 | 90.63 Billion KRW | 8.0% |
| 2019 Q3 | 82.64 Billion KRW | 5.21% |
| 2019 Q2 | 78.55 Billion KRW | -5.89% |
| 2019 Q1 | 83.47 Billion KRW | 17.69% |
| 2019 FY | 82.99 Billion KRW | 17.02% |
| 2019 Q4 | 82.99 Billion KRW | 0.42% |
| 2018 Q4 | 70.92 Billion KRW | 19.56% |
| 2018 Q2 | 68.11 Billion KRW | 23.48% |
| 2018 Q1 | 55.16 Billion KRW | 15.9% |
| 2018 FY | 70.92 Billion KRW | 49.03% |
| 2018 Q3 | 59.32 Billion KRW | -12.9% |
| 2017 Q3 | 40.49 Billion KRW | -11.92% |
| 2017 Q4 | 47.59 Billion KRW | 17.52% |
| 2017 FY | 47.59 Billion KRW | 21.5% |
| 2017 Q1 | 41.3 Billion KRW | 5.46% |
| 2017 Q2 | 45.97 Billion KRW | 11.3% |
| 2016 Q1 | 34.48 Billion KRW | -30.48% |
| 2016 FY | 39.17 Billion KRW | -21.02% |
| 2016 Q4 | 39.17 Billion KRW | 15.69% |
| 2016 Q3 | 33.85 Billion KRW | -1.84% |
| 2016 Q2 | 34.49 Billion KRW | 0.04% |
| 2015 Q3 | 63.12 Billion KRW | 2945.01% |
| 2015 Q2 | 2.07 Billion KRW | -45.27% |
| 2015 Q1 | 3.78 Billion KRW | -6.0% |
| 2015 FY | 49.59 Billion KRW | 1130.78% |
| 2015 Q4 | 49.59 Billion KRW | -21.43% |
| 2014 FY | 4.02 Billion KRW | 51.02% |
| 2014 Q4 | 4.02 Billion KRW | 30.95% |
| 2014 Q2 | 2.74 Billion KRW | 16.26% |
| 2014 Q1 | 2.36 Billion KRW | -11.55% |
| 2014 Q3 | 3.07 Billion KRW | 12.16% |
| 2013 FY | 2.66 Billion KRW | 0.0% |
| 2013 Q3 | 6.18 Billion KRW | 0.0% |
| 2013 Q4 | 2.66 Billion KRW | -56.87% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | -46.407% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -13095.553% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -227.834% |
| Bioneer Corporation | 80.61 Billion KRW | -207.806% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -1141.444% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | -82.8% |
| CrystalGenomics, Inc. | 97.82 Billion USD | -153.647% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -237.32% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 76.794% |
| Medy-Tox Inc. | 137.14 Billion KRW | -80.927% |
| Peptron, Inc. | 16.36 Billion KRW | -1415.821% |
| Genexine, Inc. | 79.68 Billion KRW | -211.389% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -747.535% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -501.063% |
| ALTEOGEN Inc. | 108.25 Billion KRW | -129.197% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -239.493% |
| SillaJen, Inc. | 19.4 Billion KRW | -1178.929% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | -38.546% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -372.716% |
| Genomictree Inc. | 7.81 Billion KRW | -3076.085% |
| MedPacto, Inc. | 9.56 Billion KRW | -2493.889% |
| D&D Pharmatech | 23.98 Billion KRW | -934.469% |
| EASY BIO,Inc. | 105.86 Billion KRW | -134.37% |
| GI Innovation, Inc. | 9.63 Billion KRW | -2474.917% |